AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 MAR 19 - (NewsRx.com & NewsRx.net) -- A pharmacoeconomic evaluation of a 7-valent pneumococcal conjugate vaccine was conducted in Canada.
"The objective of this study was to evaluate the projected health benefits, costs, and cost-effectiveness of pneumococcal conjugate vaccination for infants and children aged
"Implementation of a pneumococcal conjugate vaccine program in Canada for each annual birth cohort of 340,000 persons observed over 10 years would be expected to save approximately 12 lives and 100,000 cases of pneumococcal disease over 10 years, resulting in total savings of CDN$67 million (Canadian dollars)," reported Marc H. Lebel and colleagues at the Universities of Montreal, Calgary, and Toronto, and at the Analytica Group and Wyeth Pharmaceuticals in the united States. "Vaccination of healthy infants would result in net savings for society if the vaccine costs less than CDN$50 per dose. Moreover, for a vaccine purchase price of CDN$67.50, infant vaccination would cost society CDN$79,000 per life-year gained."
The researchers concluded, "Pneumococcal conjugate vaccination is a potentially cost-effective means of pneumococcal disease ...
Source: HighBeam Research, Canadian researchers evaluate 7-valent pneumococcal conjugate vaccine.